Please note that some translations using Google Translate may not be accurately represented, and image captions and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result for using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Chronic myelogenous leukemia (CML) is a cancer of the blood. It affects a particular type of white blood cells called myeloid cells, or “myeloblasts.”
Children and teens with leukemia are treated through the
Leukemia Program at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. Dana-Farber/Boston Children’s has played a key role in refining treatment for childhood leukemia, and we continue to be a world leader in
childhood leukemia clinical trials designed to increase cure rates, decrease treatment-related side effects and improve care for long-term survivors. The Leukemia Program also offers families the chance to have their child's leukemia cells molecularly profiled, which may help identify opportunities for
in-depth information on chronic myelogenous leukemia (CML) on the Dana-Farber/Boston Children's website, including details on CML symptoms, diagnosis and treatment.
Appointments and Second Opinions